{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:12:33Z","timestamp":1780593153266,"version":"3.54.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00428-022-03402-8","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T03:19:39Z","timestamp":1662520779000},"page":"85-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Updates on eosinophilic disorders"],"prefix":"10.1007","volume":"482","author":[{"given":"Alexandar","family":"Tzankov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaaren K.","family":"Reichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9911","authenticated-orcid":false,"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"issue":"3","key":"3402_CR1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","volume":"130","author":"P Valent","year":"2012","unstructured":"Valent P et al (2012) Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130(3):607\u201361 e9","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"3402_CR2","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ajh.25247","volume":"93","author":"Z Hu","year":"2018","unstructured":"Hu Z et al (2018) A multimodality work-up of patients with Hypereosinophilia. Am J Hematol 93(11):1337\u20131346","journal-title":"Am J Hematol"},{"issue":"1","key":"3402_CR3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.26352","volume":"97","author":"W Shomali","year":"2022","unstructured":"Shomali W, Gotlib J (2022) World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(1):129\u2013148","journal-title":"Am J Hematol"},{"issue":"4","key":"3402_CR4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/bjh.14488","volume":"176","author":"NM Butt","year":"2017","unstructured":"Butt NM et al (2017) Guideline for the investigation and management of eosinophilia. Br J Haematol 176(4):553\u2013572","journal-title":"Br J Haematol"},{"issue":"20","key":"3402_CR5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"key":"3402_CR6","doi-asserted-by":"publisher","unstructured":"Arber DA et al (2022) International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. https:\/\/doi.org\/10.1182\/blood.2022015850","DOI":"10.1182\/blood.2022015850"},{"key":"3402_CR7","unstructured":"Bain, BJ, Gilliland, DG, Horny, HP, Vardiman, JW. (2008) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1, in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, SH. Swerdlow, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, Thiele, J, Vardiman, JW, Editor. 2008, International Agency for Research on Cancer (IARC): Lyon. p. 68 - 73."},{"issue":"6","key":"3402_CR8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","volume":"129","author":"A Reiter","year":"2017","unstructured":"Reiter A, Gotlib J (2017) Myeloid neoplasms with eosinophilia. Blood 129(6):704\u2013714","journal-title":"Blood"},{"issue":"2","key":"3402_CR9","first-page":"614","volume":"106","author":"J Yao","year":"2021","unstructured":"Yao J et al (2021) Myeloid\/lymphoid neoplasms with eosinophilia\/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition. Haematologica 106(2):614\u2013618","journal-title":"Haematologica"},{"issue":"7","key":"3402_CR10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25825","volume":"95","author":"J Schwaab","year":"2020","unstructured":"Schwaab J et al (2020) Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol 95(7):824\u2013833","journal-title":"Am J Hematol"},{"key":"3402_CR11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cancergen.2018.08.002","volume":"228\u2013229","author":"W Xie","year":"2018","unstructured":"Xie W et al (2018) Myeloproliferative neoplasm with ABL1\/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors. Cancer Genet 228\u2013229:41\u201346","journal-title":"Cancer Genet"},{"issue":"9","key":"3402_CR12","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3324\/haematol.2016.144345","volume":"101","author":"M Zaliova","year":"2016","unstructured":"Zaliova M et al (2016) Characterization of leukemias with ETV6-ABL1 fusion. Haematologica 101(9):1082\u20131093","journal-title":"Haematologica"},{"issue":"2","key":"3402_CR13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3324\/haematol.2010.036673","volume":"96","author":"F Perna","year":"2011","unstructured":"Perna F et al (2011) ETV6-ABL1-positive \u201cchronic myeloid leukemia\u201d: clinical and molecular response to tyrosine kinase inhibition. Haematologica 96(2):342\u2013343","journal-title":"Haematologica"},{"issue":"1","key":"3402_CR14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2141.1995.tb03407.x","volume":"90","author":"JW Janssen","year":"1995","unstructured":"Janssen JW et al (1995) The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event. Br J Haematol 90(1):222\u2013224","journal-title":"Br J Haematol"},{"issue":"11","key":"3402_CR15","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1128\/MCB.24.11.4685-4695.2004","volume":"24","author":"RP Million","year":"2004","unstructured":"Million RP et al (2004) A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol 24(11):4685\u20134695","journal-title":"Mol Cell Biol"},{"issue":"1","key":"3402_CR16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.2010.08457.x","volume":"153","author":"T Ernst","year":"2011","unstructured":"Ernst T et al (2011) Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. Br J Haematol 153(1):43\u201346","journal-title":"Br J Haematol"},{"issue":"19","key":"3402_CR17","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","volume":"130","author":"SK Tasian","year":"2017","unstructured":"Tasian SK, Loh ML, Hunger SP (2017) Philadelphia chromosome-like acute lymphoblastic leukemia. Blood 130(19):2064\u20132072","journal-title":"Blood"},{"issue":"5","key":"3402_CR18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0609.2011.01586.x","volume":"86","author":"E De Braekeleer","year":"2011","unstructured":"De Braekeleer E et al (2011) ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol 86(5):361\u2013371","journal-title":"Eur J Haematol"},{"key":"3402_CR19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cancergen.2019.07.004","volume":"238","author":"MH Cessna","year":"2019","unstructured":"Cessna MH et al (2019) Chronic myelomonocytic leukemia with ETV6-ABL1 rearrangement and SMC1A mutation. Cancer Genet 238:31\u201336","journal-title":"Cancer Genet"},{"key":"3402_CR20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12308-014-0203-6","volume":"7","author":"N Hosseini","year":"2014","unstructured":"Hosseini N et al (2014) ETV6\/FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophilia. J Hematopath 7:7","journal-title":"J Hematopath"},{"issue":"8","key":"3402_CR21","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","volume":"118","author":"C Walz","year":"2011","unstructured":"Walz C et al (2011) Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood 118(8):2239\u20132242","journal-title":"Blood"},{"issue":"3","key":"3402_CR22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00277-013-1843-9","volume":"93","author":"K Chonabayashi","year":"2014","unstructured":"Chonabayashi K et al (2014) Successful allogeneic stem cell transplantation with long-term remission of ETV6\/FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia. Ann Hematol 93(3):535\u2013537","journal-title":"Ann Hematol"},{"issue":"2","key":"3402_CR23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/leu.2016.304","volume":"31","author":"E Troadec","year":"2017","unstructured":"Troadec E et al (2017) A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of FLT3? Leukemia 31(2):514\u2013517","journal-title":"Leukemia"},{"key":"3402_CR24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cancergen.2017.05.001","volume":"216\u2013217","author":"A Chung","year":"2017","unstructured":"Chung A et al (2017) A novel TRIP11-FLT3 fusion in a patient with a myeloid\/lymphoid neoplasm with eosinophilia. Cancer Genet 216\u2013217:10\u201315","journal-title":"Cancer Genet"},{"key":"3402_CR25","doi-asserted-by":"crossref","unstructured":"Munthe-Kaas, MC, et al. (2020) Partial Response to Sorafenib in a Child With a Myeloid\/Lymphoid Neoplasm, Eosinophilia, and a ZMYM2-FLT3 Fusion. J Pediatr Hematol Oncol","DOI":"10.1097\/MPH.0000000000001890"},{"issue":"10","key":"3402_CR26","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/leu.2014.168","volume":"28","author":"L Falchi","year":"2014","unstructured":"Falchi L et al (2014) ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia 28(10):2090\u20132092","journal-title":"Leukemia"},{"issue":"8","key":"3402_CR27","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2404266","volume":"20","author":"HA Vu","year":"2006","unstructured":"Vu HA et al (2006) FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 20(8):1414\u20131421","journal-title":"Leukemia"},{"issue":"10","key":"3402_CR28","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/leu.2017.240","volume":"31","author":"M Jawhar","year":"2017","unstructured":"Jawhar M et al (2017) Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia. Leukemia 31(10):2271\u20132273","journal-title":"Leukemia"},{"key":"3402_CR29","doi-asserted-by":"crossref","unstructured":"Zhang, H, et al. (2018) Two myeloid leukemia cases with rare FLT3 fusions. Cold Spring Harb Mol Case Stud. 4(6)","DOI":"10.1101\/mcs.a003079"},{"issue":"11","key":"3402_CR30","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.exphem.2007.07.002","volume":"35","author":"FH Grand","year":"2007","unstructured":"Grand FH et al (2007) A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Exp Hematol 35(11):1723\u20131727","journal-title":"Exp Hematol"},{"issue":"2","key":"3402_CR31","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41375-019-0549-y","volume":"34","author":"AK Chao","year":"2020","unstructured":"Chao AK et al (2020) Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia 34(2):662\u2013666","journal-title":"Leukemia"},{"issue":"8","key":"3402_CR32","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/jcp.2008.058073","volume":"61","author":"A Tzankov","year":"2008","unstructured":"Tzankov A et al (2008) Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. J Clin Pathol 61(8):958\u2013961","journal-title":"J Clin Pathol"},{"key":"3402_CR33","doi-asserted-by":"crossref","first-page":"106460","DOI":"10.1016\/j.leukres.2020.106460","volume":"99","author":"H Shao","year":"2020","unstructured":"Shao H et al (2020) Myeloid\/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. Leuk Res 99:106460","journal-title":"Leuk Res"},{"issue":"9","key":"3402_CR34","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/s41379-021-00817-7","volume":"34","author":"G Tang","year":"2021","unstructured":"Tang G et al (2021) Myeloid\/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol 34(9):1673\u20131685","journal-title":"Mod Pathol"},{"issue":"7","key":"3402_CR35","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","volume":"65","author":"A Reiter","year":"2005","unstructured":"Reiter A et al (2005) The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65(7):2662\u20132667","journal-title":"Cancer Res"},{"issue":"6","key":"3402_CR36","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","volume":"166","author":"BJ Bain","year":"2014","unstructured":"Bain BJ, Ahmad S (2014) Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol 166(6):809\u2013817","journal-title":"Br J Haematol"},{"issue":"10","key":"3402_CR37","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.humpath.2005.07.020","volume":"36","author":"S Heiss","year":"2005","unstructured":"Heiss S et al (2005) Myelodysplastic\/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case. Hum Pathol 36(10):1148\u20131151","journal-title":"Hum Pathol"},{"issue":"4","key":"3402_CR38","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41379-018-0165-9","volume":"32","author":"G Tang","year":"2019","unstructured":"Tang G et al (2019) Hematopoietic neoplasms with 9p24\/JAK2 rearrangement: a multicenter study. Mod Pathol 32(4):490\u2013498","journal-title":"Mod Pathol"},{"issue":"2","key":"3402_CR39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ajcp\/aqaa208","volume":"155","author":"O Pozdnyakova","year":"2021","unstructured":"Pozdnyakova O et al (2021) Myeloid\/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2. Am J Clin Pathol 155(2):160\u2013178","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"3402_CR40","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2019004410","volume":"136","author":"C Luedke","year":"2020","unstructured":"Luedke C, Rein L (2020) Transformation to erythroblastic sarcoma from myeloid neoplasm with PCM1-JAK2. Blood 136(9):1113","journal-title":"Blood"},{"issue":"17","key":"3402_CR41","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/bloodadvances.2020004174","volume":"5","author":"JA Chen","year":"2021","unstructured":"Chen JA et al (2021) Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Adv 5(17):3492\u20133496","journal-title":"Blood Adv"},{"key":"3402_CR42","doi-asserted-by":"crossref","unstructured":"Kaplan, HG, et al.(2022) PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature. Oncologist","DOI":"10.1093\/oncolo\/oyac072"},{"issue":"7","key":"3402_CR43","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1182\/blood-2012-06-433821","volume":"120","author":"E Lierman","year":"2012","unstructured":"Lierman E et al (2012) Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)\/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood 120(7):1529\u20131531","journal-title":"Blood"},{"issue":"11","key":"3402_CR44","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","volume":"94","author":"E Rumi","year":"2015","unstructured":"Rumi E et al (2015) Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol 94(11):1927\u20131928","journal-title":"Ann Hematol"},{"issue":"2","key":"3402_CR45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","volume":"94","author":"J Schwaab","year":"2015","unstructured":"Schwaab J et al (2015) Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol 94(2):233\u2013238","journal-title":"Ann Hematol"},{"issue":"10","key":"3402_CR46","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/gcc.20585","volume":"47","author":"JL Poitras","year":"2008","unstructured":"Poitras JL et al (2008) Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 47(10):884\u20139","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"3402_CR47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/bloodadvances.2017014704","volume":"2","author":"TH Tran","year":"2018","unstructured":"Tran TH et al (2018) Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Adv 2(5):529\u2013533","journal-title":"Blood Adv"},{"issue":"8","key":"3402_CR48","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.3324\/haematol.2017.187302","volume":"103","author":"C Baer","year":"2018","unstructured":"Baer C et al (2018) Molecular genetic characterization of myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2. Haematologica 103(8):e348\u2013e350","journal-title":"Haematologica"},{"issue":"5","key":"3402_CR49","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2141.2010.08394.x","volume":"151","author":"MC Rapanotti","year":"2010","unstructured":"Rapanotti MC et al (2010) Molecular characterization of paediatric idiopathic hypereosinophilia. Br J Haematol 151(5):440\u2013446","journal-title":"Br J Haematol"},{"issue":"24","key":"3402_CR50","volume":"101","author":"L Gao","year":"2022","unstructured":"Gao L et al (2022) A rare cause of persistent leukocytosis with massive splenomegaly: Myeloid neoplasm with BCR-PDGFRA rearrangement-Case report and literature review. Medicine (Baltimore) 101(24):e29179","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"3402_CR51","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2010-05-286757","volume":"117","author":"C Elling","year":"2011","unstructured":"Elling C et al (2011) Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 117(10):2935\u20132943","journal-title":"Blood"},{"issue":"22","key":"3402_CR52","doi-asserted-by":"crossref","first-page":"33229","DOI":"10.18632\/oncotarget.8906","volume":"7","author":"SQ Qu","year":"2016","unstructured":"Qu SQ et al (2016) Long-term outcomes of imatinib in patients with FIP1L1\/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Oncotarget 7(22):33229\u201333236","journal-title":"Oncotarget"},{"issue":"5","key":"3402_CR53","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","volume":"23","author":"E Lierman","year":"2009","unstructured":"Lierman E et al (2009) FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 23(5):845\u2013851","journal-title":"Leukemia"},{"issue":"4","key":"3402_CR54","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.exphem.2013.12.007","volume":"42","author":"I Sadovnik","year":"2014","unstructured":"Sadovnik I et al (2014) Identification of Ponatinib as a potent inhibitor of growth migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. Exp Hematol 42(4):282-293 e4","journal-title":"Exp Hematol"},{"key":"3402_CR55","doi-asserted-by":"crossref","unstructured":"Fang H et al (2020) Systematic Use of Fluorescence in situ Hybridization (FISH) and Clinicopathological Features in the Screening of PDGFRB Rearrangements of Patients with Myeloid\/Lymphoid Neoplasms. Histopathology","DOI":"10.1111\/his.14097"},{"issue":"10","key":"3402_CR56","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.6004\/jnccn.2020.7573","volume":"18","author":"SK Gupta","year":"2020","unstructured":"Gupta SK et al (2020) A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw 18(10):1300\u20131304","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"3402_CR57","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/bloodadvances.2019001182","volume":"4","author":"M Jan","year":"2020","unstructured":"Jan M et al (2020) A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood Adv 4(3):445\u2013448","journal-title":"Blood Adv"},{"issue":"7","key":"3402_CR58","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","volume":"59","author":"P Strati","year":"2018","unstructured":"Strati P et al (2018) Myeloid\/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma 59(7):1672\u20131676","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"3402_CR59","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10245332.2018.1446279","volume":"23","author":"K Umino","year":"2018","unstructured":"Umino K et al (2018) Clinical outcomes of myeloid\/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement. Hematology 23(8):470\u2013477","journal-title":"Hematology"},{"issue":"1","key":"3402_CR60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0b013e31814b226e","volume":"32","author":"F Vega","year":"2008","unstructured":"Vega F et al (2008) t(8;13)-positive bilineal lymphomas: report of 6 cases. Am J Surg Pathol 32(1):14\u201320","journal-title":"Am J Surg Pathol"},{"key":"3402_CR61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.humpath.2017.05.008","volume":"65","author":"X Montenegro-Garreaud","year":"2017","unstructured":"Montenegro-Garreaud X et al (2017) Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)\/BCR-FGFR1:a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase. Hum Pathol 65:147\u2013156","journal-title":"Hum Pathol"},{"issue":"1","key":"3402_CR62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/16078454.2020.1854493","volume":"26","author":"M Chen","year":"2021","unstructured":"Chen M et al (2021) Myeloid\/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosis. Hematology 26(1):153\u2013159","journal-title":"Hematology"},{"issue":"8","key":"3402_CR63","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/annonc\/mdy173","volume":"29","author":"S Verstovsek","year":"2018","unstructured":"Verstovsek S et al (2018) Treatment of the myeloid\/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. Ann Oncol 29(8):1880\u20131882","journal-title":"Ann Oncol"},{"issue":"3","key":"3402_CR64","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41409-021-01553-x","volume":"57","author":"JC Hernandez-Boluda","year":"2022","unstructured":"Hernandez-Boluda JC et al (2022) Allogeneic hematopoietic cell transplantation in patients with myeloid\/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplant 57(3):416\u2013422","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"3402_CR65","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/his.14097","volume":"76","author":"H Fang","year":"2020","unstructured":"Fang H et al (2020) Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid\/lymphoid neoplasms. Histopathology 76(7):1042\u20131054","journal-title":"Histopathology"},{"key":"3402_CR66","doi-asserted-by":"crossref","unstructured":"Strati, P, et al. (2017) Myeloid\/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 1\u20135","DOI":"10.1080\/10428194.2017.1397663"},{"key":"3402_CR67","first-page":"4158567","volume":"2016","author":"LE Brown","year":"2016","unstructured":"Brown LE et al (2016) A 26-Year-Old Female with Systemic Mastocytosis with Associated Myeloid Neoplasm with Eosinophilia and Abnormalities of PDGFRB, t(4;5)(q21;q33). Case Rep Hematol 2016:4158567","journal-title":"Case Rep Hematol"},{"issue":"2","key":"3402_CR68","first-page":"801","volume":"7","author":"CB Duckworth","year":"2014","unstructured":"Duckworth CB, Zhang L, Li S (2014) Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case. Int J Clin Exp Pathol 7(2):801\u20137","journal-title":"Int J Clin Exp Pathol"},{"issue":"10","key":"3402_CR69","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","volume":"104","author":"A Pardanani","year":"2004","unstructured":"Pardanani A et al (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104(10):3038\u20133045","journal-title":"Blood"},{"issue":"11","key":"3402_CR70","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts KG et al (2014) Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371(11):1005\u20131015","journal-title":"N Engl J Med"},{"issue":"11","key":"3402_CR71","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.exphem.2007.08.025","volume":"35","author":"V Najfeld","year":"2007","unstructured":"Najfeld V et al (2007) Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol 35(11):1668\u20131676","journal-title":"Exp Hematol"},{"issue":"8","key":"3402_CR72","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","volume":"132","author":"KG Roberts","year":"2018","unstructured":"Roberts KG et al (2018) Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children\u2019s Oncology Group. Blood 132(8):815\u2013824","journal-title":"Blood"},{"issue":"6","key":"3402_CR73","doi-asserted-by":"crossref","first-page":"708","DOI":"10.6004\/jnccn.2016.0072","volume":"14","author":"W Wang","year":"2016","unstructured":"Wang W et al (2016) Cytogenetic Evolution Associated With Disease Progression in Hematopoietic Neoplasms With t(8;22)(p11;q11)\/BCR-FGFR1 Rearrangement. J Natl Compr Canc Netw 14(6):708\u2013711","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"3402_CR74","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00281-021-00863-y","volume":"43","author":"P Valent","year":"2021","unstructured":"Valent P et al (2021) Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity. Semin Immunopathol 43(3):423\u2013438","journal-title":"Semin Immunopathol"},{"issue":"8","key":"3402_CR75","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","volume":"29","author":"SA Wang","year":"2016","unstructured":"Wang SA et al (2016) Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol 29(8):854\u2013864","journal-title":"Mod Pathol"},{"issue":"9","key":"3402_CR76","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2016.73","volume":"30","author":"A Pardanani","year":"2016","unstructured":"Pardanani A et al (2016) Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. Leukemia 30(9):1924\u20131926","journal-title":"Leukemia"},{"issue":"10","key":"3402_CR77","volume":"12","author":"JS Lee","year":"2017","unstructured":"Lee JS et al (2017) Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing. PLoS ONE 12(10):e0185602","journal-title":"PLoS ONE"},{"issue":"2","key":"3402_CR78","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","volume":"33","author":"NCP Cross","year":"2019","unstructured":"Cross NCP et al (2019) Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia 33(2):415\u2013425","journal-title":"Leukemia"},{"issue":"2","key":"3402_CR79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ajcp\/aqaa244","volume":"155","author":"K Kelemen","year":"2021","unstructured":"Kelemen K et al (2021) Eosinophilia\/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders. Am J Clin Pathol 155(2):179\u2013210","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"3402_CR80","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","volume":"102","author":"SA Wang","year":"2017","unstructured":"Wang SA et al (2017) Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica 102(8):1352\u20131360","journal-title":"Haematologica"},{"issue":"5","key":"3402_CR81","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/ajcp\/aqy064","volume":"150","author":"H Fang","year":"2018","unstructured":"Fang H et al (2018) A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience. Am J Clin Pathol 150(5):421\u2013431","journal-title":"Am J Clin Pathol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03402-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-022-03402-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03402-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T19:17:47Z","timestamp":1674847067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-022-03402-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3402"],"URL":"https:\/\/doi.org\/10.1007\/s00428-022-03402-8","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"26 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The review follows the ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}